Switched memory B cells maintain specific memory independently of serum antibodies: The hepatitis B example
Open accessAbstract
The immunogenicity of a vaccine is conventionally measured through the level of serum Abs early after immunization, but to ensure protection specific Abs should be maintained long after primary vaccination. For hepatitis B, protective levels often decline over time, but breakthrough infections do not seem to occur. The aim of this study was to demonstrate whether, after hepatitis B vaccination, B‐cell memory persists even when serum Abs decline. We compared the frequency of anti‐hepatitis‐specific memory B cells that remain in the blood of 99 children five years after priming with Infanrix®‐hexa (GlaxoSmithKline) (n=34) or with Hexavac® (Sanofi Pasteur MSD) (n=65). These two vaccines differ in their ability to generate protective levels of IgG. Children with serum Abs under the protective level, <10 mIU/mL, received a booster dose of hepatitis B vaccine, and memory B cells and serum Abs were measured 2 wk later. We found that specific memory B cells had a similar frequency in all children independently of primary vaccine. Booster injection resulted in the increase of memory B cell frequencies (from 11.3 in 10 6 cells to 28.2 in 10 6 cells, p<0.01) and serum Abs (geometric mean concentration, GMC from 2.9 to 284 mIU/mL), demonstrating that circulating memory B cells effectively respond to Ag challenge even when specific Abs fall under the protective threshold.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There are many scenarios where circulating antibodies may not achieve sterilizing immunity and additional immune responses from memory cells will be necessary.
“there are many scenarios where circulating antibodies may not achieve sterilizing immunity and additional immune responses from memory cells will be necessary (36).”
From Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination (2021) · cites this paper as [36]
Clinical hepatitis after hepatitis B virus infection is prevented by immune memory even without vaccine-elicited circulating antibodies, because HBV disease progresses slowly.
“clinical hepatitis after hepatitis B virus (HBV) infection is prevented by immune memory even without vaccine-elicited circulating antibodies, because of the relatively slow course of HBV disease”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Rosado et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 40 · Cited by 61
- Authors
- Rosado, M. M., Scarsella, M., Pandolfi, E., Cascioli, S., Giorda, E., Chionne, P., Madonne, E., Gesualdo, F., Romano, M., Ausiello, C. M., Rapicetta, M., Zanetti, A. R., Tozzi, A., & Carsetti, R.
- Affiliations
- Bambino Gesù Children's Hospital (IT)
- Istituto Superiore di Sanità (IT)
- University of Milan (IT)
- Corresponding author
- Carsetti, Rita
- ORCID
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2011-05-25
- Volume
- 41
- Issue
- 6
- Pages
- 1800-1808
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1964704877
- Cited by
- 61
- References
- 40
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 8 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 5 · 2015: 5 · 2014: 8 · 2013: 5 · 2012: 9
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (other-oa)
- Funders
- Agenzia Italiana del Farmaco, Ministero della Salute
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- hepatitis B vaccine, memory B cells, serum antibodies, booster vaccination, antibody waning, vaccine immunogenicity, children, Infanrix Hexa, breakthrough infection, long-term vaccine protection
- MeSH terms
- B-Lymphocytes, Cell Count, Child, Female, Hepatitis B, Hepatitis B Antibodies, Hepatitis B virus, Humans, Immunization Schedule, Immunologic Memory, Male, Poliovirus Vaccine, Inactivated, Diphtheria-Tetanus-Pertussis Vaccine, B-Lymphocyte Subsets, Hepatitis B Vaccines, Vaccines, Combined, Haemophilus Vaccines, Diphtheria-Tetanus-acellular Pertussis Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review